shutterstock_1140355787_piotr_swat
Piotr Swat / Shutterstock.com
1 March 2019Americas

US FTC settles pay-for-delay case with AbbVie

The US Federal Trade Commission (FTC) concluded a ten-year pay-for-delay suit yesterday, with  AbbVie agreeing not to enter certain settlements in patent cases that delay market entry of generic drugs.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
25 July 2013   The chair of the FTC has said it will continue to challenge pay-for-delay court settlements in the pharmaceutical industry and has hailed a Supreme Court ruling as a victory for consumers.
Americas
6 November 2017   Pharmaceutical companies have entered into fewer potential ‘pay-for-delay’ patent settlements for the second year in a row, following the US Supreme Court’s decision in FTC v Actavis.
Big Pharma
15 October 2020   Twenty US states, the US Federal Trade Commission, and consumer groups have asked the Seventh Circuit of the US Court of Appeals to reconsider a case claiming that AbbVie strived to prevent competition to its immunosuppressant drug, Humira.

More on this story

Americas
25 July 2013   The chair of the FTC has said it will continue to challenge pay-for-delay court settlements in the pharmaceutical industry and has hailed a Supreme Court ruling as a victory for consumers.
Americas
6 November 2017   Pharmaceutical companies have entered into fewer potential ‘pay-for-delay’ patent settlements for the second year in a row, following the US Supreme Court’s decision in FTC v Actavis.
Big Pharma
15 October 2020   Twenty US states, the US Federal Trade Commission, and consumer groups have asked the Seventh Circuit of the US Court of Appeals to reconsider a case claiming that AbbVie strived to prevent competition to its immunosuppressant drug, Humira.

More on this story

Americas
25 July 2013   The chair of the FTC has said it will continue to challenge pay-for-delay court settlements in the pharmaceutical industry and has hailed a Supreme Court ruling as a victory for consumers.
Americas
6 November 2017   Pharmaceutical companies have entered into fewer potential ‘pay-for-delay’ patent settlements for the second year in a row, following the US Supreme Court’s decision in FTC v Actavis.
Big Pharma
15 October 2020   Twenty US states, the US Federal Trade Commission, and consumer groups have asked the Seventh Circuit of the US Court of Appeals to reconsider a case claiming that AbbVie strived to prevent competition to its immunosuppressant drug, Humira.